Biomarin Capital Stock from 2010 to 2025

BMRN Stock

USD 71.99 0.75 1.05%

Biomarin Pharmaceutical Capital Stock yearly trend continues to be very stable with very little volatility. Capital Stock is likely to grow to about 202.7 K this year. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

191 K

Current Value

202.7 K

Quarterly Volatility

7 K

Credit Downgrade

Yuan Drop

Covid

Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.2 M, Interest Expense of 17.9 M or Selling General Administrative of 558.9 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.91. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Biomarin Pharmaceutical over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Biomarin Pharmaceutical's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Biomarin Capital Stock Regression Statistics

	Arithmetic Mean	182,295
	Geometric Mean	182,175
	Coefficient Of Variation	3.82
	Mean Deviation	5,155
	Median	178,000
	Standard Deviation	6,956
	Sample Variance	48.4M
	Range	24.7K
	R-Value	0.81
	Mean Square Error	18.2M
	R-Squared	0.65
	Significance	0.0002
	Slope	1,178
	Total Sum of Squares	725.7M

Biomarin Capital Stock History

	2025	202.7 K
	2024	191 K
	2023	189 K
	2022	186 K
	2021	184 K
	2020	182 K
	2019	180 K

Other Fundumenentals of Biomarin Pharmaceutical

Issuance Of Capital Stock

Biomarin Pharmaceutical Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.03	-0.11	0.4	0.95	0.78	0.97	0.41	0.46	-0.14	0.77	0.64	0.98	0.42	0.79	0.97	0.84	0.9	0.73	-0.48	0.8	0.67	0.74
Total Stockholder Equity	0.99		-0.09	0.01	0.31	0.97	0.68	0.97	0.31	0.37	-0.22	0.69	0.56	0.97	0.37	0.73	0.99	0.82	0.85	0.7	-0.46	0.85	0.73	0.82
Net Debt	0.03	-0.09		-0.64	0.38	-0.16	0.54	-0.09	0.55	0.65	0.04	0.34	0.42	0.04	0.0	0.39	-0.12	0.06	0.26	0.19	-0.16	-0.21	-0.37	-0.47
Retained Earnings	-0.11	0.01	-0.64		-0.84	0.09	-0.57	-0.06	-0.76	-0.65	-0.35	-0.55	-0.44	-0.22	-0.39	-0.5	0.1	-0.03	-0.39	-0.26	0.53	0.44	0.47	0.45
Accounts Payable	0.4	0.31	0.38	-0.84		0.26	0.66	0.35	0.79	0.5	0.4	0.66	0.33	0.51	0.51	0.71	0.21	0.2	0.61	0.52	-0.54	-0.12	-0.21	-0.11
Net Receivables	0.95	0.97	-0.16	0.09	0.26		0.6	0.96	0.18	0.29	-0.21	0.61	0.41	0.93	0.28	0.64	0.97	0.75	0.79	0.62	-0.4	0.86	0.72	0.85
Total Liab	0.78	0.68	0.54	-0.57	0.66	0.6		0.71	0.68	0.71	0.18	0.92	0.82	0.78	0.48	0.86	0.63	0.76	0.89	0.68	-0.41	0.44	0.28	0.18
Total Current Assets	0.97	0.97	-0.09	-0.06	0.35	0.96	0.71		0.27	0.45	-0.11	0.72	0.58	0.96	0.41	0.69	0.96	0.82	0.84	0.62	-0.44	0.8	0.7	0.78
Intangible Assets	0.41	0.31	0.55	-0.76	0.79	0.18	0.68	0.27		0.58	0.22	0.65	0.55	0.48	0.42	0.78	0.2	0.29	0.58	0.57	-0.51	-0.1	-0.11	-0.14
Short Term Investments	0.46	0.37	0.65	-0.65	0.5	0.29	0.71	0.45	0.58		-0.08	0.58	0.66	0.49	0.24	0.61	0.33	0.43	0.59	0.31	-0.51	0.08	0.09	-0.01
Short Term Debt	-0.14	-0.22	0.04	-0.35	0.4	-0.21	0.18	-0.11	0.22	-0.08		0.18	0.04	-0.13	0.41	-0.05	-0.28	-0.07	-0.09	0.03	0.28	-0.35	-0.42	-0.32
Common Stock	0.77	0.69	0.34	-0.55	0.66	0.61	0.92	0.72	0.65	0.58	0.18		0.79	0.78	0.37	0.81	0.61	0.72	0.86	0.66	-0.44	0.42	0.35	0.2
Long Term Debt	0.64	0.56	0.42	-0.44	0.33	0.41	0.82	0.58	0.55	0.66	0.04	0.79		0.62	0.41	0.63	0.53	0.74	0.69	0.37	-0.26	0.36	0.36	0.12
Property Plant Equipment	0.98	0.97	0.04	-0.22	0.51	0.93	0.78	0.96	0.48	0.49	-0.13	0.78	0.62		0.44	0.82	0.93	0.78	0.91	0.7	-0.56	0.71	0.6	0.7
Current Deferred Revenue	0.42	0.37	0.0	-0.39	0.51	0.28	0.48	0.41	0.42	0.24	0.41	0.37	0.41	0.44		0.52	0.36	0.48	0.53	0.51	-0.38	0.13	0.08	0.12
Good Will	0.79	0.73	0.39	-0.5	0.71	0.64	0.86	0.69	0.78	0.61	-0.05	0.81	0.63	0.82	0.52		0.67	0.72	0.94	0.8	-0.59	0.46	0.4	0.26
Net Tangible Assets	0.97	0.99	-0.12	0.1	0.21	0.97	0.63	0.96	0.2	0.33	-0.28	0.61	0.53	0.93	0.36	0.67		0.82	0.82	0.65	-0.41	0.89	0.78	0.84
Long Term Debt Total	0.84	0.82	0.06	-0.03	0.2	0.75	0.76	0.82	0.29	0.43	-0.07	0.72	0.74	0.78	0.48	0.72	0.82		0.85	0.62	-0.25	0.8	0.78	0.48
Capital Surpluse	0.9	0.85	0.26	-0.39	0.61	0.79	0.89	0.84	0.58	0.59	-0.09	0.86	0.69	0.91	0.53	0.94	0.82	0.85		0.77	-0.56	0.63	0.54	0.41
Long Term Investments	0.73	0.7	0.19	-0.26	0.52	0.62	0.68	0.62	0.57	0.31	0.03	0.66	0.37	0.7	0.51	0.8	0.65	0.62	0.77		-0.58	0.53	0.34	0.4
Short Long Term Debt	-0.48	-0.46	-0.16	0.53	-0.54	-0.4	-0.41	-0.44	-0.51	-0.51	0.28	-0.44	-0.26	-0.56	-0.38	-0.59	-0.41	-0.25	-0.56	-0.58		-0.1	-0.08	-0.23
Net Invested Capital	0.8	0.85	-0.21	0.44	-0.12	0.86	0.44	0.8	-0.1	0.08	-0.35	0.42	0.36	0.71	0.13	0.46	0.89	0.8	0.63	0.53	-0.1		0.88	0.8
Net Working Capital	0.67	0.73	-0.37	0.47	-0.21	0.72	0.28	0.7	-0.11	0.09	-0.42	0.35	0.36	0.6	0.08	0.4	0.78	0.78	0.54	0.34	-0.08	0.88		0.69
Capital Stock	0.74	0.82	-0.47	0.45	-0.11	0.85	0.18	0.78	-0.14	-0.01	-0.32	0.2	0.12	0.7	0.12	0.26	0.84	0.48	0.41	0.4	-0.23	0.8	0.69

Click cells to compare fundamentals

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Capital Stock, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

		Last Reported	Projected for Next Year
	Capital Stock	191 K	202.7 K

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

6.449

Earnings Share

2.21

Revenue Per Share

15.018

Quarterly Revenue Growth

0.156

Return On Assets

0.0515

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Capital Stock from 2010 to 2025

Latest Biomarin Pharmaceutical's Capital Stock Growth Pattern

Biomarin Capital Stock Regression Statistics

Biomarin Capital Stock History

Other Fundumenentals of Biomarin Pharmaceutical

Biomarin Pharmaceutical Capital Stock component correlations

About Biomarin Pharmaceutical Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY